Ramucirumab is the first biological treatment given as a single drug that has survival benefits in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma progressing after first-line chemotherapy, according to Prof. Charles Fuchs and the REGARD Trial Investigators who published results from an international, randomised, multicentre, placebo-controlled, phase III trial in The Lancet. Read more here.
Study mentioned: Fuchs CS, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2013 Oct 1. pii: S0140-6736(13)61719-5. [Epub ahead of print] PMID: 24094768
No comments:
Post a Comment